Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of SBC-102 in adults with lysosomal acid lipase deficiency and liver dysfunction
2011-001513-13Phase 2Completed
- Sponsor
- Synageva BioPharma
- Start
- Aug 2011
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD), sponsored by Synageva BioPharma. Primary endpoints: Adverse events, Vital signs, physical examination, ECG, and clinical laboratory changes and 2 more. Started Aug 2011; status: completed.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)
Beyond the preview
Go deeper on 2011-001513-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001513-13.